Share

Related Links

Related Stories

  • Proceedings of the 2nd Annual London Genetics Pharmacogenetics conference 2010 Pharmacogenetics: Why, How and When?
    The importance of pharmacogenetics and stratified medicine as part of the drug development processes is now widely acknowledge, offering the opportunity to address many of the challenges facing the biopharmaceutical industry today and supporting an era where cost-effectiveness and value-based pricing rule. Moving on from the inaugural London Genetics Pharmacogenetic conference in 2009, at which the role of pharmacogenetics in drug discovery and development was debated, the 2nd London Genetics conference, entitled ‘Pharmacogenetics – Why, How and When?’ focused on how and when to apply stratified approaches from drug discovery through to cost-effectiveness evaluation and reimbursement.
  • Catching up on Circulating Tumor Cell Technology
    Circulating tumor cells (CTCs) are cells that ‘escape’ from primary tumor cells and migrate into the bloodstream, where they circulate through the body. CTCs were first identified in the 1980s as cells that had the morphology of tumor cells but were found in the blood. Over the past two decades technological innovations have eased the detection and analysis of CTCs. The resulting investigations of CTCs are an important area of clinical research because they are demonstrating that CTCs have potential clinical value as warning signals of cancer progression.
  • Why stem cells don't just want to make neurons
    Research being presented today (01 April) at the UK National Stem Cell Network annual science conference provides another piece in the puzzle of why it can be so hard to produce large numbers of the same type of cell in the lab - a process that is vital for scaling up stem cell production for therapeutic use. This knowledge will help researchers to develop strategies for obtaining the desired cell type for use in either research or medicine.
  • The View From Here: Pharmacogenetics in the real world – everything you need to know about how to use it
    The compelling arguments for the use of pharmacogenetics in drug development are well known and rehearsed.
  • Enterprise hub foundations laid at Colworth Science Park
    Construction work is underway on The Exchange, a new enterprise hub at Colworth Science Park that is being developed by Unilever and Goodman.

Top 5 Stories

News

IDBS and Genentech present state-of-the-art next-generation electronic lab notebooks at the 8th Annual ELN and Advanced Lab Solutions Conference

25 September 2009

ID Business Services (IDBS) announced yesterday that IDBS customer Dr Martin Vanderlaan, Director, Analytical Operations at Genentech, will present ‘Implementing an Electronic Lab Notebook for a Large Bioprocess Organisation’ at IQPC’s ELN and Advanced Lab Solutions Conference in Brussels, Belgium.

Dr Paul Denny-Gouldson, Product Manager at IDBS, will also present a session on ‘Data Management as the Foundation of ELNs as a Knowledge Base’.

Dr Vanderlaan’s case study will highlight the pilot implementation of an ELN solution, covering the IT roadmap for a completely electronic records environment, organizational change management, the best strategy and planning for ELN selection and implementation, and key lessons learned. Dr Denny-Gouldson’s session will demonstrate how the right data management technology can support cross-study, cross-project, and cross-domain search and reporting. Examples of workflows gathered from across the industry will be presented including the ‘One Click IND’ and ‘Automated Compound Progression’ and how these require both data management and data federation to be successful.

Dr Vanderlaan has been with Genentech for 14 years, most recently as the Director of Analytical Operations. Previously, he was Director of Immunochemistry, Perseptive Biosystems Head, Hybidoma Group, Lawrence Livermore National Laboratory. He is a technical expert in Analysis of BioPharmaceuticals using chromatography, immunoassays, and potency assays and has authored more than 80 publications and patents. Dr Vanderlaan holds a PhD from New York University Medical School and an MBA from the University of San Francisco. Dr Denny-Gouldson has almost 15 years’ experience in pharmacology, pharmaceutical drug development and ELN software development. He joined IDBS in 2005 when the company he founded, Deffinity Solutions, was purchased by IDBS. Before this, he was Senior Scientist at Sanofi-Synthelabo (now Sanofi-Aventis). Dr Denny-Gouldson obtained his PhD in Computational Biology from Essex University in 1996 and has authored over 20 scientific papers and book chapters.

The ELN and Lab Solutions conference will be held 29–30 September, 2009, at The Renaissance Hotel, Brussels, Belgium. Dr Denny-Gouldson will present on September 29 at 11:45 am, and Dr Vanderlaan will present on September 29 at 3:45 pm. For more information on the conference and these sessions, visit http://www.elnforum.com/index.php.
 

 

This article is featured in:
Companies and People

 

Comment on this article

You must be registered and logged in to leave a comment about this article.